|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000149256 |
Summary for TENM4 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000149256 | Gene symbol | TENM4 |
| Gene name | teneurin transmembrane protein 4 | |
| HGNC | 29945 | |
| Entrez ID | 26011 | |
| Gene type | protein_coding | |
| Synonyms | TENM4|KIAA1302|Ten-M4|TEN4 | |
| UniProtAcc | Q6N022 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for TENM4 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| TENM4 | 1.80e+03 | -1.06e+00 | 2.91e-01 | -3.66e+00 | 2.56e-04 | 8.24e-04 | THCA |
| Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Top |
Sex-biased somatic mutation for TENM4 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for TENM4 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg04983516 | chr11:79440675 | CGI:chr11:79437314-79441160 | promoter,exon,gene body | 4.20e-02 | 1.61e-01 | -2.00e+00 | 4.56e-02 | 4.83e-02 | -1.19e-01 |
| BRCA | cg12841273 | chr11:79440144 | CGI:chr11:79437314-79441160 | promoter,gene body | 6.52e-02 | 2.37e-01 | -3.25e+00 | 1.14e-03 | 1.02e-02 | -1.71e-01 |
| BRCA | cg14697835 | chr11:79440158 | CGI:chr11:79437314-79441160 | promoter,gene body | 7.75e-02 | 2.33e-01 | -3.24e+00 | 1.19e-03 | 1.05e-02 | -1.56e-01 |
| BRCA | cg05218311 | chr11:79440747 | CGI:chr11:79437314-79441160 | promoter,exon,gene body | 1.65e-01 | 3.12e-01 | -2.11e+00 | 3.48e-02 | 4.35e-02 | -1.47e-01 |
| BRCA | cg19884965 | chr11:79439261 | CGI:chr11:79437314-79441160 | promoter,gene body | 2.64e-01 | 4.44e-01 | -3.49e+00 | 4.77e-04 | 5.86e-03 | -1.81e-01 |
| BRCA | cg14309111 | chr11:79439367 | CGI:chr11:79437314-79441160 | promoter,gene body | 2.47e-01 | 3.66e-01 | -2.04e+00 | 4.09e-02 | 4.64e-02 | -1.20e-01 |
| BRCA | cg09673208 | chr11:79440767 | CGI:chr11:79437314-79441160 | promoter,exon,gene body | 1.01e-01 | 2.69e-01 | -2.91e+00 | 3.57e-03 | 1.78e-02 | -1.68e-01 |
| BRCA | cg05099909 | chr11:79440770 | CGI:chr11:79437314-79441160 | promoter,exon,gene body | 7.18e-02 | 1.91e-01 | -2.46e+00 | 1.38e-02 | 3.03e-02 | -1.19e-01 |
| LIHC | cg00908927 | chr11:79441925 | CGI:chr11:79437314-79441160 | promoter | 4.70e-01 | 3.55e-01 | 2.93e+00 | 3.44e-03 | 8.69e-03 | 1.15e-01 |
| DLBC | cg25965355 | chr11:79440922 | CGI:chr11:79437314-79441160 | promoter,exon,gene body | 3.72e-01 | 2.71e-01 | 4.16e+00 | 3.20e-05 | 1.90e-04 | 1.02e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg00908927 | chr11:79441925 | CGI:chr11:79437314-79441160 | promoter | 6.71e-01 | 8.48e-01 | -5.50e+00 | 3.77e-08 | 2.19e-07 | -1.78e-01 |
| LUSC | cg22782986 | chr11:79441777 | CGI:chr11:79437314-79441160 | promoter | 3.92e-01 | 9.47e-02 | 3.82e+00 | 1.33e-04 | 7.94e-04 | 2.97e-01 |
| LUSC | cg00908927 | chr11:79441925 | CGI:chr11:79437314-79441160 | promoter | 6.91e-01 | 5.42e-01 | 3.14e+00 | 1.68e-03 | 3.70e-03 | 1.50e-01 |
| COAD | cg22782986 | chr11:79441777 | CGI:chr11:79437314-79441160 | promoter | 5.38e-01 | 4.15e-01 | 2.35e+00 | 1.89e-02 | 2.37e-02 | 1.23e-01 |
| LIHC | cg05218311 | chr11:79440747 | CGI:chr11:79437314-79441160 | promoter,exon,gene body | 1.74e-01 | 7.33e-02 | 4.82e+00 | 1.42e-06 | 5.02e-06 | 1.01e-01 |
| LIHC | cg00908927 | chr11:79441925 | CGI:chr11:79437314-79441160 | promoter | 3.55e-01 | 6.41e-01 | -4.39e+00 | 1.13e-05 | 3.03e-05 | -2.86e-01 |
| KIRP | cg03648711 | chr11:79438997 | CGI:chr11:79437314-79441160 | promoter,exon,gene body | 3.26e-01 | 5.49e-02 | 2.70e+00 | 7.02e-03 | 9.50e-03 | 2.71e-01 |
| KIRP | cg19884965 | chr11:79439261 | CGI:chr11:79437314-79441160 | promoter,gene body | 3.94e-01 | 2.54e-01 | 2.40e+00 | 1.62e-02 | 1.93e-02 | 1.40e-01 |
| KIRP | cg14309111 | chr11:79439367 | CGI:chr11:79437314-79441160 | promoter,gene body | 3.17e-01 | 1.23e-01 | 2.19e+00 | 2.88e-02 | 3.13e-02 | 1.94e-01 |
| CHOL | cg22782986 | chr11:79441777 | CGI:chr11:79437314-79441160 | promoter | 3.86e-01 | 1.40e-01 | 2.36e+00 | 1.83e-02 | 2.92e-02 | 2.47e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg19884965 | chr11:79439261 | CGI:chr11:79437314-79441160 | promoter,gene body | 2.64e-01 | 1.47e-01 | 8.61e+00 | 7.47e-18 | 3.39e-17 | 1.17e-01 |
| BRCA | cg14309111 | chr11:79439367 | CGI:chr11:79437314-79441160 | promoter,gene body | 2.47e-01 | 1.02e-01 | 8.76e+00 | 2.00e-18 | 9.51e-18 | 1.45e-01 |
| BRCA | cg22782986 | chr11:79441777 | CGI:chr11:79437314-79441160 | promoter | 5.28e-01 | 4.12e-01 | 4.47e+00 | 7.83e-06 | 1.33e-05 | 1.16e-01 |
| KIRC | cg14309111 | chr11:79439367 | CGI:chr11:79437314-79441160 | promoter,gene body | 2.42e-01 | 9.50e-02 | 2.61e+00 | 9.07e-03 | 1.60e-02 | 1.47e-01 |
| HNSC | cg00908927 | chr11:79441925 | CGI:chr11:79437314-79441160 | promoter | 6.77e-01 | 8.39e-01 | -2.70e+00 | 6.87e-03 | 1.54e-02 | -1.62e-01 |
Top |
Exon skipping events with PSI in TCGA for TENM4 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for TENM4 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for TENM4 |
| TFs related to TENM4. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| TENM4 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for TENM4 |
| RBPs related to ES in TENM4. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| TENM4 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs189406150 | chr11:73885628:G:T | - | 0.127195078806865 | 0.0426048442814018 | LGG | Female-baised eQTL |
| rs7936065 | chr11:87890246:A:G | - | 0.0432082694746026 | 0.0390742590951304 | LUAD | Female-baised eQTL |
| rs7945528 | chr11:87889756:C:T | - | 0.045458985531273 | 0.041886647205706 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs11827379 | chr11:69631784:A:G | - | 0.166792515895863 | 0.0262931557666075 | SARC | Male-baised eQTL |
| rs1941379 | chr11:78796745:A:G | gene | 0.0668277485027428 | 0.0201420127145527 | LUAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000149256 |
| CpG Site: cg26452771 | |
| Position to Gene: gene | |
| Male Effect: - | |
| Female Effect: -0.138401998176654 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg26452771 | chr11:79244574 | gene | -0.138401998176654 | 1.5167908265335e-08 | -0.41859268705562547 | 1.8015825235717307e-11 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of TENM4 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000149256 | TENM4 | C0005586 | Bipolar Disorder | 1 | CTD_human |
| ENSG00000149256 | TENM4 | C0005587 | Depression, Bipolar | 1 | CTD_human |
| ENSG00000149256 | TENM4 | C0024713 | Manic Disorder | 1 | CTD_human |
| ENSG00000149256 | TENM4 | C0033975 | Psychotic Disorders | 1 | PSYGENET |
| ENSG00000149256 | TENM4 | C0036341 | Schizophrenia | 1 | PSYGENET |
| ENSG00000149256 | TENM4 | C0338831 | Manic | 1 | CTD_human |
| ENSG00000149256 | TENM4 | C0349204 | Nonorganic psychosis | 1 | PSYGENET |
| ENSG00000149256 | TENM4 | C4225223 | TREMOR, HEREDITARY ESSENTIAL, 5 | 1 | CTD_human |
